GLENMARK LIFE SCIENCES Financial Statement Analysis
|
||
|
The Revenues of GLENMARK LIFE SCIENCES have increased by 1.79% YoY .
The Earnings Per Share (EPS) of GLENMARK LIFE SCIENCES has increased by 0.84 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
GLENMARK LIFE SCIENCES Last 5 Annual Financial Results
[BOM: 543322|NSE : GLS]
| Standalone | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹2,161 Cr | ₹2,123 Cr | ₹1,885 Cr | ₹1,537 Cr | ₹886 Cr |
| Expenses | ₹1,519 Cr | ₹1,507 Cr | ₹1,294 Cr | ₹1,065 Cr | ₹639 Cr |
| Operating Profit (Excl OI) | ₹642 Cr | ₹616 Cr | ₹591 Cr | ₹472 Cr | ₹247 Cr |
| Other Income | ₹29 Cr | ₹15 Cr | ₹0.81 Cr | ₹12 Cr | ₹0.99 Cr |
| Interest | ₹0.55 Cr | ₹28 Cr | ₹88 Cr | ₹34 Cr | ₹0.61 Cr |
| Depreciation | ₹42 Cr | ₹38 Cr | ₹33 Cr | ₹29 Cr | ₹19 Cr |
| Profit Before Tax | ₹629 Cr | ₹565 Cr | ₹471 Cr | ₹421 Cr | ₹228 Cr |
| Profit After Tax | ₹467 Cr | ₹419 Cr | ₹352 Cr | ₹313 Cr | ₹196 Cr |
| Earnings Per Share (Rs) | ₹38.43 | ₹38.11 | ₹34.17 | ₹358.76 | ₹1,597.44 |
| PAT Margin (%) | 20.56 | 21.49 | 19.70 | 18.60 | 20.34 |
| ROE(%) | 21.15 | 22.33 | 29.87 | 60.91 | 127.84 |
| ROCE(%) | 28.31 | 30.01 | 42.24 | 96.75 | 185.60 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 12,849.0 Cr |
| Revenue (TTM) | : | ₹ 2,204.9 Cr |
| Net Profit(TTM) | : | ₹ 423.5 Cr |
| EPS (TTM) | : | ₹ 34.6 |
| P/E (TTM) | : | 30.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLENMARK LIFE SCIENCES | 1.9% | -2.7% | 71.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -6.3% | 49.2% |
| CIPLA | -2.6% | -3.8% | 19.2% |
| DR REDDYS LABORATORIES | -4.1% | -10.8% | 9.5% |
| ZYDUS LIFESCIENCES | -2% | -6.1% | 49.9% |
| DIVIS LABORATORIES | 3.5% | 0.9% | 66.2% |
| MANKIND PHARMA | 0.9% | -3.4% | 37% |
| TORRENT PHARMACEUTICALS | -0.6% | -8.5% | 51.8% |
| LUPIN | 0.2% | -4.9% | 70.6% |
GLENMARK LIFE SCIENCES Revenues
[BOM: 543322|NSE : GLS]
| Y-o-Y | 1.79 % |
| 5 Yr CAGR | 24.96 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,161 Cr | 1.79 | |
| Mar2023 | ₹2,123 Cr | 12.63 | |
| Mar2022 | ₹1,885 Cr | 22.63 | |
| Mar2021 | ₹1,537 Cr | 73.43 | |
| Mar2020 | ₹886 Cr | - | |
GLENMARK LIFE SCIENCES Operating Profit
[BOM: 543322|NSE : GLS]
| Y-o-Y | 4.26 % |
| 5 Yr CAGR | 26.96 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹642 Cr | 4.26 | |
| Mar2023 | ₹616 Cr | 4.23 | |
| Mar2022 | ₹591 Cr | 25.24 | |
| Mar2021 | ₹472 Cr | 90.94 | |
| Mar2020 | ₹247 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 2.41 % |
| 5 Yr CAGR | 1.61 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 29.72% | 2.41 | |
| Mar2023 | 29.02% | -7.43 | |
| Mar2022 | 31.35% | 2.12 | |
| Mar2021 | 30.7% | 10.11 | |
| Mar2020 | 27.88% | - | |
GLENMARK LIFE SCIENCES Profit After Tax
[BOM: 543322|NSE : GLS]
| Y-o-Y | 11.52 % |
| 5 Yr CAGR | 24.30 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹467 Cr | 11.52 | |
| Mar2023 | ₹419 Cr | 19.10 | |
| Mar2022 | ₹352 Cr | 12.29 | |
| Mar2021 | ₹313 Cr | 60.08 | |
| Mar2020 | ₹196 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -4.33 % |
| 5 Yr CAGR | 0.27 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 20.56 % | -4.33 | |
| Mar2023 | 21.49 % | 9.09 | |
| Mar2022 | 19.7 % | 5.91 | |
| Mar2021 | 18.6 % | -8.55 | |
| Mar2020 | 20.34 % | - | |
GLENMARK LIFE SCIENCES Earnings Per Share (EPS)
[BOM: 543322|NSE : GLS]
| Y-o-Y | 0.84 % |
| 5 Yr CAGR | -60.62 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹38 | 0.84 | |
| Mar2023 | ₹38 | 11.53 | |
| Mar2022 | ₹34 | -90.48 | |
| Mar2021 | ₹359 | -77.54 | |
| Mar2020 | ₹1,597 | - | |
GLENMARK LIFE SCIENCES Return on Capital Employed (ROCE)
[BOM: 543322|NSE : GLS]
| Y-o-Y | -5.66 % |
| 5 Yr CAGR | -37.51 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 28.31% | -5.66 | |
| Mar2023 | 30.01% | -28.95 | |
| Mar2022 | 42.24% | -56.34 | |
| Mar2021 | 96.75% | -47.87 | |
| Mar2020 | 185.6% | - | |
GLENMARK LIFE SCIENCES Share Price vs Sensex
| Current Share Price | : | ₹1,048.9 |
| Current MarketCap | : | ₹ 12,849.0 Cr |
| Updated EOD on | : | Nov 22,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK LIFE SCIENCES | 1.9% |
-2.7% |
71.4% |
| SENSEX | -1.9% |
-5% |
17.5% |
GLENMARK LIFE SCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE HEALTHCARE | -1.8% | -4.1% | 46.6% |
| S&P BSE MIDSMALLCAP | -2.3% | -7.5% | 33.6% |
| S&P BSE SMALL CAP | -2.7% | -7.7% | 32.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 MULTICAP 50:25:25 | -2.3% | -7.2% | 26.5% |
You may also like the below Video Courses
FAQ about GLENMARK LIFE SCIENCES Financials
How the annual revenues of GLENMARK LIFE SCIENCES have changed ?
The Revenues of GLENMARK LIFE SCIENCES have increased by 1.79% YoY .
How the Earnings per Share (EPS) of GLENMARK LIFE SCIENCES have changed?
The Earnings Per Share (EPS) of GLENMARK LIFE SCIENCES has increased by 0.84 % YoY .
Check out Intrinsic Value of Peers of GLENMARK LIFE SCIENCES
Compare Stock Analytics of Peers of GLENMARK LIFE SCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
